-
1.发明授权Methods using recombinant anti-epidermal growth factor receptor antibody compositions 有权使用重组抗表皮生长因子受体抗体组合物的方法公开(公告)号：US08663640B2
公开(公告)日：2014-03-04
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
公开(公告)号：US20110129855A1
公开(公告)日：2011-06-02
申请号：US12945495
申请日：2010-11-12
申请人： MIKKEL WANDAHL PEDERSEN , LUCILLA STEINAA , ALLAN JENSEN , KLAUS KOEFOED , PER-JOHAN MEIJER , ROBERT CARLSSON , CHARLES PYKE , LARS SOGAARD NIELSEN
发明人： MIKKEL WANDAHL PEDERSEN , LUCILLA STEINAA , ALLAN JENSEN , KLAUS KOEFOED , PER-JOHAN MEIJER , ROBERT CARLSSON , CHARLES PYKE , LARS SOGAARD NIELSEN
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
-
公开(公告)号：US20090004192A1
公开(公告)日：2009-01-01
申请号：US12074056
申请日：2008-02-29
申请人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meuer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
发明人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meuer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
IPC分类号： A61K39/395 , G01N33/566 , C12N15/12 , C07K14/47 , C07K16/22 , C12N15/85 , A61P35/00 , C12P21/02 , C12N5/16 , C12N5/10
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
公开(公告)号：US08609095B2
公开(公告)日：2013-12-17
申请号：US13040029
申请日：2011-03-03
IPC分类号： A61K39/395
摘要： The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions comprising at least two of said recombinant anti-HER2 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
摘要翻译： 本发明涉及针对HER2（ErbB2）的新型治疗性抗体，以及包含至少两种所述重组抗HER2抗体的重组多克隆抗HER2抗体组合物，以及抗体和抗体组合物用于治疗癌症的用途。
-
公开(公告)号：US07887805B2
公开(公告)日：2011-02-15
申请号：US12074056
申请日：2008-02-29
申请人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars S. Nielsen
发明人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars S. Nielsen
IPC分类号： A61K39/395 , C07K14/71 , C12N15/13
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示出基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
公开(公告)号：US09217039B2
公开(公告)日：2015-12-22
申请号：US13882807
申请日：2011-10-31
IPC分类号： A61K39/395 , C07K16/40 , C07K16/28 , C07K16/32 , A61K39/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
摘要翻译： 本发明涉及针对HER3（ErbB3）的新型治疗性重组抗体，以及包含至少两种所述重组抗HER3抗体的混合物的组合物，以及抗体和抗体组合物用于治疗癌症的用途。
-
公开(公告)号：US20130287684A1
公开(公告)日：2013-10-31
申请号：US13882807
申请日：2011-10-31
IPC分类号： C07K16/40 , A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/32 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer.
摘要翻译： 本发明涉及针对HER3（ErbB3）的新型治疗性重组抗体，以及包含至少两种所述重组抗HER3抗体的混合物的组合物，以及抗体和抗体组合物用于治疗癌症的用途。
-
公开(公告)号：US08414896B2
公开(公告)日：2013-04-09
申请号：US12945527
申请日：2010-11-12
申请人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
发明人： Mikkel Wandahl Pedersen , Lucilla Steinaa , Allan Jensen , Klaus Koefoed , Per-Johan Meijer , Robert Carlsson , Charles Pyke , Lars Sogaard Nielsen
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , C07K14/71
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/507 , C07K14/71 , C07K2317/31 , C07K2317/54 , C07K2317/565 , C07K2317/92 , A61K2300/00
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies showed synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供能够结合人EGFR的抗体的组合物或混合物。 具有3种或更多种抗体的抗体组合物在代表性癌细胞系的增殖减少方面表现出协同作用。 使用包含两种不同的嵌合抗hEGFR抗体的组合物也获得了有利的结果，其显示基于动物模型中快速且有效的受体内化，诱导终末分化和随后的肿瘤根除的新作用机制。 本发明的抗体可以作为多克隆抗体在一个生物反应器中制造。
-
公开(公告)号：US20110229463A1
公开(公告)日：2011-09-22
申请号：US13061417
申请日：2009-08-27
IPC分类号： A61K39/395 , C07K16/32 , C12N5/09 , A61P35/00
CPC分类号： C07K16/2863 , A61K2039/507 , C07K14/71 , C07K2317/24 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要： The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumours following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumours. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.
摘要翻译： 本发明涉及用于人类癌症治疗的重组抗体领域。 更具体地，本发明提供了对人EGFR具有两种不同的非重叠结合特异性的抗体组合物的用途。 抗体组合物在用其他抗EGFR抗体治疗后，无论癌症是否在先前治疗期间或之后显示进展，都在治疗癌症中。 在本发明的抗体组合物一线治疗后，抗体组合物也可用于重复治疗复发性肿瘤，因为该组合物不导致抗性肿瘤的选择。 进一步的治疗用途是使用本发明的抗体组合物治疗对已知抗EGFR抗体具有抗性的癌症。
-
10.发明申请METHOD FOR IDENTIFYING AND SELECTING DRUG CANDIDATES FOR COMBINATORIAL DRUG PRODUCTS 审中-公开识别和选择用于组合药物制品的药物候选药物的方法公开(公告)号：US20110224094A1
公开(公告)日：2011-09-15
申请号：US13122713
申请日：2009-10-06
CPC分类号： G01N33/6854 , A61K2039/507 , C07K16/00 , C07K16/2863 , G01N33/6845
摘要： A method for identifying and selecting chemical entities that contributes to a functional effect in the development of new combinatorial drugs. The combinations of two or more chemical compounds show a synergistic effect. The compounds can be e.g. antibodies, antibiotics, anti-cancer agents, anti-AIDS agents, anti-growth factors, antiviral agents, soluble receptors, cytokines, RNAi's, vaccines and mixtures thereof. The method comprises a) providing n samples each comprising a chemical entity, b) mixing 2 or more of the n samples in all possible combinations, c) subjecting this mixture to a functional assay in order to identify entities contributing to the functional effect. The steps a-c are repeated on the chemical entities from step c which contribute to the functional effect.
摘要翻译： 用于鉴定和选择有助于开发新组合药物的功能效应的化学物质的方法。 两种或更多种化合物的组合显示出协同效应。 化合物可以是例如 抗体，抗生素，抗癌剂，抗艾滋病剂，抗生长因子，抗病毒剂，可溶性受体，细胞因子，RNAi，疫苗及其混合物。 该方法包括a）提供每个包含化学实体的n个样品，b）以所有可能的组合混合2个或更多个n个样品，c）使该混合物进行功能测定，以鉴定有助于功能效应的实体。 对来自步骤c的有助于功能效应的化学实体重复步骤a-c。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.026 秒)
